Selection Bias in High-dose Chemotherapy (HDCT) Trials
Single arm trials suggested higher response rates and survival rates for HDCT in women with breast cancer
Outcome for 1581 patients with metastatic breast cancer treated with conventional doxorubicin-based regimens, not HDCT: (J Clin Oncol 15:3171,1997)